Head of Research, Krungthai XSpring

Waraporn Wiboonkanarak

Head of Research

A full service Thai brokerage

Krungthai XSpring

Krungthai XSpring is a full service broker. The company provides a wide range of investment services such as Securities Brokerage, Derivative Agent Business, Securities Borrowing and Lending, Securities Trading, Underwriting, Financial Advisory, Wealth Advisory, Private Fund Management and International Markets Securities Trading. 

In terms of credibility, Fitch Ratings has assigned Krunghtai XSpring a long-term rating of AA- and a national short-term rating of F1+ with stable outlook.

Thematic (Sector/Industry)

<ul><li>Asian bourses closed mixed despite gains in the US market, while the SET fluctuated within a narrow range before slipping back to the 1,300-point level.</li><li>The recent decline in the index is viewed as profit-taking amid light trading volume and the absence of heavy selling pressure on large-cap stocks that could dampen sentiment.</li><li>We expect the index to edge down only slightly, as selling pressure remains limited and buying interest in large-cap stocks persists.</li></ul>

Asian bourses closed mixed despite gains in the US market, while the SET fluctuated within a narrow range before slipping back to the 1,300-point level.The recent decline in the index is viewed as profit-taking amid light trading volume and the absence of heavy selling pressure on large-cap stocks that could dampen sentiment.We expect the index to edge down only slightly, as selling pressure remains limited and buying interest in large-cap stocks persists.

Krungthai XSpring Technical Eng. November 12, 2025

<ul><li>Asian bourses surged as optimism grew that the US government shutdown might soon end, while investors shifted their focus to 3Q25 earnings results and economic stimulus measures.</li><li>The index continued to hover around the 1,300-point level, forming a solid base.</li><li>Hence, we maintain a buy-on-dip strategy, acknowledging that subdued trading volume may lead to continued short-term fluctuations.</li></ul>

Asian bourses surged as optimism grew that the US government shutdown might soon end, while investors shifted their focus to 3Q25 earnings results and economic stimulus measures.The index continued to hover around the 1,300-point level, forming a solid base.Hence, we maintain a buy-on-dip strategy, acknowledging that subdued trading volume may lead to continued short-term fluctuations.

Krungthai XSpring Technical Eng. November 11, 2025

<ul><li>Concerns that the AI sector may be entering a bubble phase, triggering selling pressure on the SET.</li><li>The index has yet to establish a clear pattern of sustained recovery, continuing to move sideways.</li><li>We maintain our “buy-on-dip” strategy, expecting the support zone to hold and offer a potential rebound opportunity.</li></ul>

Concerns that the AI sector may be entering a bubble phase, triggering selling pressure on the SET.The index has yet to establish a clear pattern of sustained recovery, continuing to move sideways.We maintain our “buy-on-dip” strategy, expecting the support zone to hold and offer a potential rebound opportunity.

Krungthai XSpring Technical Eng. November 10, 2025

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyzed the changes in short interest of Stock Exchange of Thailand as of Nov 7th. We estimate that they had an aggregated short interest worth USD2.3bn.</li>
<li>We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in Intouch, Bumrungrad Hospital, Bangkok Bank, Bangkok Dusit, True, Bangkok Dusit, Bumrungrad Hospital, True, Bangkok Bank.</li>
</ul>


We analyzed the changes in short interest of Stock Exchange of Thailand as of Nov 7th. We estimate that they had an aggregated short interest worth USD2.3bn.
We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in Intouch, Bumrungrad Hospital, Bangkok Bank, Bangkok Dusit, True, Bangkok Dusit, Bumrungrad Hospital, True, Bangkok Bank.


Thailand Short Interest Weekly (Nov 7th): Intouch, Bumrungrad Hospital, Bangkok Bank, Bangkok Dusit

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>Celltrion inlicensed two antibody-based new drug candidates for the treatment of autoimmune diseases in KRW1T deal. Dong-A ST received approval for epilepsy drug, Xcopri, developed by SK Biopharmaceuticals in Korea.</li>
<li>Hanmi Pharmaceutical will distribute and sell three major COPD treatments developed by Boehringer Ingelheim. Shandong Boan Biotechnology’s marketing application for denosumab biosimilar has been accepted in the UK.  </li>
<li>Eisai has settled patent infringement litigation with Torrent Pharmaceuticals related to Lenvima in the U.S. Otsuka Holdings initiated Phase 3 clinical trial evaluating quabodepistat, for the treatment of multidrug-resistant tuberculosis.</li>
</ul>


Celltrion inlicensed two antibody-based new drug candidates for the treatment of autoimmune diseases in KRW1T deal. Dong-A ST received approval for epilepsy drug, Xcopri, developed by SK Biopharmaceuticals in Korea.
Hanmi Pharmaceutical will distribute and sell three major COPD treatments developed by Boehringer Ingelheim. Shandong Boan Biotechnology’s marketing application for denosumab biosimilar has been accepted in the UK.  
Eisai has settled patent infringement litigation with Torrent Pharmaceuticals related to Lenvima in the U.S. Otsuka Holdings initiated Phase 3 clinical trial evaluating quabodepistat, for the treatment of multidrug-resistant tuberculosis.


APAC Healthcare Weekly (November 9) – Celltrion, Dong-A ST, Hanmi Pharm, Boan Bio, Eisai, Otsuka

Thailand

Bangkok Dusit Medical Services Public Company Limited operates Bangkok General Hospital. The Hospital specializes in cardiovascular, lung, neurological, eye and genitourinary cancer, as well as physical therapy and medical imaging.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Bangkok Dusit Medical Services (BDMS TB)

Krungthai XSpring Technical Eng. November 12, 2025

Asian bourses closed mixed despite gains in the US market, while the SET fluctuated within a narrow range before slipping back to the 1,300-point...

Krungthai XSpring

Krungthai XSpring Technical Eng. November 11, 2025

Asian bourses surged as optimism grew that the US government shutdown might soon end, while investors shifted their focus to 3Q25 earnings results...

Krungthai XSpring

Krungthai XSpring Technical Eng. November 10, 2025

Concerns that the AI sector may be entering a bubble phase, triggering selling pressure on the SET. The index has yet to establish a clear pattern...

Krungthai XSpring

Thailand Short Interest Weekly (Nov 7th): Intouch, Bumrungrad Hospital, Bangkok Bank, Bangkok Dusit

We analyzed SET short interest report for the past week and highlighted short interest changes in Intouch (INTUCH TB), Bumrungrad Hospital (BH TB),...

Ke Yan, CFA, FRM

APAC Healthcare Weekly (November 9) – Celltrion, Dong-A ST, Hanmi Pharm, Boan Bio, Eisai, Otsuka

Celltrion inlicensed two antibody drug candidates in KRW1T deal. Dong-A got domestic approval for Xcopri. Hanmi Pharm will distribute Boehringer...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)